GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study

Keyphrases

• Advanced Ovarian Cancer 100%
• Neoadjuvant Chemotherapy 100%
• Dose-escalation Study 100%
• Interleukin-12 (IL-12) 40%
• Dose-limiting Toxicity 40%
• Epithelial Ovarian Cancer 40%
• Tumor Microenvironment 40%
• Debulking 40%
• Confidence Interval 20%
• Immunological Response 20%
• Antitumor Activity 20%
• Diarrhea 20%
• Neutropenia 20%
• Nausea 20%
• Immunosuppression 20%
• Abdominal Pain 20%
• Cholesterol 20%
• Maximum Tolerated Dose 20%
• Dose Escalation 20%
• Newly Diagnosed 20%
• Pathological Complete Response 20%
• CD8+ T Cells 20%
• Cancer Model 20%
• Carboplatin 20%
• Weekly Paclitaxel 20%
• Median Time 20%
• Complete Response 20%
• Partial Response 20%
• Plasmid 20%
• Polyethylene Glycol 20%
• Taxanes 20%
• Carboplatin-paclitaxel 20%
• Treatment-related Adverse Events 20%
• Patient Experience 20%
• Interferon-γ 20%
• Peritoneal Fluid 20%
• Stage IIIC 20%
• Intention-to-treat 20%
• Vomiting 20%
• Time to Treatment Failure 20%
• Anorexia 20%
• Myeloid Dendritic Cells 20%
• Effector Memory T Cells 20%
• Radiological Response 20%
• Intravenous Chemotherapy 20%
• Intraperitoneal Infusion 20%
• Peritoneal Washing 20%
• Lipopolymer 20%
• Polyethyleneimine 20%

Medicine and Dentistry

• Krukenberg Tumor 100%
• Neoadjuvant Chemotherapy 100%
• Carboplatin 40%
• Paclitaxel 40%
• Tumor Microenvironment 40%
• Debulking 40%
• Cytokine 20%
• Nausea 20%
• Adverse Event 20%
• Neutropenia 20%
• Diarrhea 20%
• Immune Response 20%
• Immunosuppressive Treatment 20%
• Abdominal Pain 20%
• Cytotoxic T-Cell 20%
• Intention-to-Treat Analysis 20%
• Intraperitoneal Drug Administration 20%
• Antineoplastic Activity 20%
• Time to Treatment 20%
• Peritoneal Fluid 20%
• Patient Experience 20%
• Anorexia 20%
• Plasmid 20%
• Cancer Model 20%
• Macrogol 20%
• Myeloid Dendritic Cell 20%
• Memory Cell 20%
• Peritoneal Washing 20%
• Polyethyleneimine 20%